BioSpace News Archive

In partnership with the VA Palo Alto Health Care System, precision oncology company Lucence is launching its first early detection study in the United States evaluating the use of its liquid biopsy technology in a screening context.

Cortexyme, Inc. (Nasdaq: CRTX) will present additional data from its Phase 2/3 GAIN Trial at the 14th Clinical Trials on Alzheimer’s Disease Conference (CTAD 2021) as a part of the meeting’s Late-Breaking Readout Roundtable program today, Thursday, November 11, 2021.

The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Jardiance® (empagliflozin) 10 mg.

BioSig Technologies, Inc., a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that it will host a live roundtable webinar to discuss the PURE EP 2.0 study results recently published in the Journal of Cardiovascular Electrophysiology.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its financial and operating results for the three and nine months ended September 30, 2021, and provided a business update.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS), today reported its third quarter 2021 operating and financial results.

Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, announced that Company management will participate in and host one-on-one meetings at the following virtual investor conferences.

GBS Inc., a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point-of-care, announced its financial results for the first quarter ended September 30, 2021, and provided a recent business update.

Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), today reported financial results for the quarter ended September 30, 2021 and provided an update on its clinical programs.

Emergent BioSolutions Inc. announced that its Board of Directors has authorized management to repurchase up to $250 million of the company’s common stock from time to time on the open market or in privately negotiated transactions.